CA1221759A - Ultrasonic imaging technique - Google Patents
Ultrasonic imaging techniqueInfo
- Publication number
- CA1221759A CA1221759A CA000446243A CA446243A CA1221759A CA 1221759 A CA1221759 A CA 1221759A CA 000446243 A CA000446243 A CA 000446243A CA 446243 A CA446243 A CA 446243A CA 1221759 A CA1221759 A CA 1221759A
- Authority
- CA
- Canada
- Prior art keywords
- predetermined area
- microparticles
- microbubbles
- mammal
- biocompatible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000003384 imaging method Methods 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 49
- 239000011859 microparticle Substances 0.000 claims abstract description 20
- 239000002872 contrast media Substances 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 22
- 210000002216 heart Anatomy 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 11
- 239000006249 magnetic particle Substances 0.000 claims description 8
- 238000002604 ultrasonography Methods 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000008121 dextrose Substances 0.000 claims description 7
- 210000004351 coronary vessel Anatomy 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 231100000252 nontoxic Toxicity 0.000 claims description 6
- 230000003000 nontoxic effect Effects 0.000 claims description 6
- 230000002093 peripheral effect Effects 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 229910002804 graphite Inorganic materials 0.000 claims description 4
- 239000010439 graphite Substances 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000013980 iron oxide Nutrition 0.000 claims description 3
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 4
- 239000000600 sorbitol Substances 0.000 claims 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 3
- 238000012285 ultrasound imaging Methods 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims 2
- 239000003570 air Substances 0.000 claims 1
- 239000006227 byproduct Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 7
- 210000001519 tissue Anatomy 0.000 description 23
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000002107 myocardial effect Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000002861 ventricular Effects 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000010412 perfusion Effects 0.000 description 7
- 210000003484 anatomy Anatomy 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 210000004789 organ system Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000005246 left atrium Anatomy 0.000 description 4
- 239000013618 particulate matter Substances 0.000 description 4
- 210000001147 pulmonary artery Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010001526 Air embolism Diseases 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 244000144987 brood Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000157282 Aesculus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000447437 Gerreidae Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01S—RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
- G01S15/00—Systems using the reflection or reradiation of acoustic waves, e.g. sonar systems
- G01S15/88—Sonar systems specially adapted for specific applications
- G01S15/89—Sonar systems specially adapted for specific applications for mapping or imaging
- G01S15/8906—Short-range imaging systems; Acoustic microscope systems using pulse-echo techniques
- G01S15/899—Combination of imaging systems with ancillary equipment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3925—Markers, e.g. radio-opaque or breast lesions markers ultrasonic
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Radar, Positioning & Navigation (AREA)
- Acoustics & Sound (AREA)
- Remote Sensing (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Computer Networks & Wireless Communication (AREA)
- General Physics & Mathematics (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
A method of ultrasonic imaging for use on medical procedures is disclosed. The method comprises injecting specifically defined microparticles or sonicated microbubbles into an animal or human to thereby alter the acoustic properties of an area to be imaged, and then ultrasonically scanning the area so as to obtain an image.
A method of ultrasonic imaging for use on medical procedures is disclosed. The method comprises injecting specifically defined microparticles or sonicated microbubbles into an animal or human to thereby alter the acoustic properties of an area to be imaged, and then ultrasonically scanning the area so as to obtain an image.
Description
ULTRASONIC IMMUNE TECHNIQUE
.. ..
BACKGROUND OF THE INVENTION
_, _ , . , . ... ... .
1. Field of the Invention This invention relates to thy f ye' d of ultrasonic imaging techniques, and more specifically, to a medical procedure which utilizes these technique as a diagnostic tool.
.. ..
BACKGROUND OF THE INVENTION
_, _ , . , . ... ... .
1. Field of the Invention This invention relates to thy f ye' d of ultrasonic imaging techniques, and more specifically, to a medical procedure which utilizes these technique as a diagnostic tool.
2 . I PD6 5 0 6 .... . ..
Various technologies exist in which parts of an animal or human body may be imaged 50 us to aid in diagnosis and therapy. Some of these existing techniques are described on this section.
One of the most well known imaging techniques involves the use of X-rays to visualize skeletal and other internal structures within aimless and human.
There are, however, a number of problems associated with the use of X-rays. Fist, some areas of the Cody may not be Arrayed awful In addition, X-rays are dangerous if the amount of exposure is excessive; further, all Ray redline absorbed over a lifetime is cumulative. Flannel whip X-rays may produce images 15 of the skeletal and other internal structures, X-rays have proved to be relatively unsatisfactory for detailed viewing of certain organ systems and blood vessel Another widely used technique is angiogra~hy7 whereby a redip dye it injected into an artery Because the dye highlights the arteries through which it flow, an X ray Jay be used to obtain an image of major, large arteries and their ~igniflcant Blanche however, angloqraphy does not permit visualization of under~p2rfused~ ischemic area of tissue or heart muscle ox the m~crocirculation. In addition, certain ang~ographic observations are based upon measurement which may vary depending upon the apparatus used, the placement and angle of lenses purity skill and similar factors D Moreover, angio~raphy is invasive in that it requires the placement of a catheter into arteries a opposed to veins Beside requiring h~spitall~ation, angiography may be dangerous.
Another technique, often referred to a radio-knucklehead imaging involves the injection of radioactive substance such as thallium, into the blood stream Thus technique doe no require invasion of the arteries as does ~n~ography~ but it does require the use ox
Various technologies exist in which parts of an animal or human body may be imaged 50 us to aid in diagnosis and therapy. Some of these existing techniques are described on this section.
One of the most well known imaging techniques involves the use of X-rays to visualize skeletal and other internal structures within aimless and human.
There are, however, a number of problems associated with the use of X-rays. Fist, some areas of the Cody may not be Arrayed awful In addition, X-rays are dangerous if the amount of exposure is excessive; further, all Ray redline absorbed over a lifetime is cumulative. Flannel whip X-rays may produce images 15 of the skeletal and other internal structures, X-rays have proved to be relatively unsatisfactory for detailed viewing of certain organ systems and blood vessel Another widely used technique is angiogra~hy7 whereby a redip dye it injected into an artery Because the dye highlights the arteries through which it flow, an X ray Jay be used to obtain an image of major, large arteries and their ~igniflcant Blanche however, angloqraphy does not permit visualization of under~p2rfused~ ischemic area of tissue or heart muscle ox the m~crocirculation. In addition, certain ang~ographic observations are based upon measurement which may vary depending upon the apparatus used, the placement and angle of lenses purity skill and similar factors D Moreover, angio~raphy is invasive in that it requires the placement of a catheter into arteries a opposed to veins Beside requiring h~spitall~ation, angiography may be dangerous.
Another technique, often referred to a radio-knucklehead imaging involves the injection of radioactive substance such as thallium, into the blood stream Thus technique doe no require invasion of the arteries as does ~n~ography~ but it does require the use ox
3, PD6506 very expensive and sophisticated machinery. Further, radio-nuclide imaging produces images of only a limited number of views of the heart, and those image may not be of exceptional clarity Finally this type of radiation it cumulative over a lifetime and may be dangerous.
Recently, there have been advances in technique for ultrasonically imaging various parts of the body, these techniques when applied to the heart in particular are known as ~echocardlography.~ on ultrasonic scanner is used to generate and receive sound waves. The ultrasonic scanner is placed on the body surface overlying the area to be imaged. The wound waves generated by the scanner are directed toward the area to be imaged The scanner then detects sound waves reflected from the underlying area and translates thaw data into images While such ultrasonic scanners are known in the art, a brief review will be set forth in order o more fully explain the present invention When ultrasonic en ray is transmitted through a substance t he acoustic properties the substance will depend upon the velocity of the transmissions and the Dennis of the substance Change on the substance's acoustic properties (or aquatic impudency will be most prounion at the interface of different substances it oldies liquid and gases). A a eonsequen~e, when ultrasonic energy is directed through various media, the changes in acoustic properties will change the reflection characteristics, resulting in a more intense wound reaction signal received by the ul~ra-~onic wanner.
Early ultrasonic imaging techniques such as echo cardiograms suffered from a lark of clarity AS a result extPn~ive efforts were undertaken to improve the ultrasonic scanners and related equipment. In addition, beginning in 1968, contrast" agents were injected into the brood stream in an effort to obtain
Recently, there have been advances in technique for ultrasonically imaging various parts of the body, these techniques when applied to the heart in particular are known as ~echocardlography.~ on ultrasonic scanner is used to generate and receive sound waves. The ultrasonic scanner is placed on the body surface overlying the area to be imaged. The wound waves generated by the scanner are directed toward the area to be imaged The scanner then detects sound waves reflected from the underlying area and translates thaw data into images While such ultrasonic scanners are known in the art, a brief review will be set forth in order o more fully explain the present invention When ultrasonic en ray is transmitted through a substance t he acoustic properties the substance will depend upon the velocity of the transmissions and the Dennis of the substance Change on the substance's acoustic properties (or aquatic impudency will be most prounion at the interface of different substances it oldies liquid and gases). A a eonsequen~e, when ultrasonic energy is directed through various media, the changes in acoustic properties will change the reflection characteristics, resulting in a more intense wound reaction signal received by the ul~ra-~onic wanner.
Early ultrasonic imaging techniques such as echo cardiograms suffered from a lark of clarity AS a result extPn~ive efforts were undertaken to improve the ultrasonic scanners and related equipment. In addition, beginning in 1968, contrast" agents were injected into the brood stream in an effort to obtain
4. PD6506 clearer or "enhanced ultrasonic images. The prior art contrast agents were liquids containing micro bubbles of gas, which sometimes were encapsulated with gelatin or saccharine and sometimes were produced by mechanically agitating, i.e. handshaking mixtures of various liquids. Other prior art contrast agents are disclosed in an article by J. Offer, et alp entitled Masonic Baxter from Contrast Produced by Collagen Microphones in ultrasonic Imaging by Academic Press, Inc. l9BO~
The contrast agents themselves are intense sound wave reflectors because of the acoustic difference between the liquid and the gas micro bubbles dissolved therein; thus, when the contrast agents are netted into and perfuse the microvasculature of tissue clearer images of such tissue may be produced however, notwithstanding the use I such contrast agents, the image produced for example of the myocardial tissue, is of relatively poor quality; is highly variable and is not quantifiable due to the variable size and persistence associated with prior art micro bubble Further, the problems of air embolism toxicity have not .
yet been investigated 3r3 SPRY OF THE INVENTION
One embodiment of the present invention is directed to an improvement associated with such prior art contrast agents by which smaller and more uniform micro bubbles are produced. A second embodiment is directed to the novel use of specifically defined metal-containing solid or semisolid contrast agents.
The Conrad agents of the present invention are I echogenic (i.e., capable ox reflecting sound waves), I small enough to pass through capillaries so as to perfuse tissue previously lnacces~ible to the prior art contrast agent injected into a peripheral venous site thereby producing enhanced image of such tissue and organs and permitting differentiation between well-perfused and poorly-perfused tissue, and (3) quantiflably reproducible In addition the metal-containlng solid or semi-solid contrast agents of the present invention are tree of the potential air embolism toxicity risks associated with the introduction of gaseous bubbles into the human or animal septum It no believed that such particulate matter has ever been used as a contrast agent in medical proceeder The method of the present inYe~tion (1) permits the imaging of organ systems which could not be imaged using prior art ultrasonic technique 7 and I permits clearer, more detailed imaging of certain area which were Lubell using such prior art techniques.
In the first embodiment of the preset invention, a viscous solution ego, 70% Dextrose 50% Dextrose, 70~ orbital Renogratin-76~ mixtures of these agents, and the like) is subjected to high frequency (Roy to Tao Ho) ultra only energy. As a royalty mierobubbles having a diameter of approximately 6 to 20 microns are produced. For ease of reference such micro bubble will be referred to herein as ~sonicated" micr~bubble~. As described in greater detail hereinbelow, such sonicated I
I PD65~6 micro bubbles have been found to be Improved con~ra5t agents .
The second embodiment of the present invention is directed to selected metal-containing micropartlcle~
used as contrast agents to reflect intense patterns of sound waves The contrast agents of the present invention are detected by conventional ultrasonic scanning equipment and translated into images in the manner described above.
The use of the microp~rticles it especially advantageous in that it orates the nerd to introduce gaseous bubbles as contrast agents in the human or animal Siam, and thus eliminates the air embolism toxicity risk inherent in that procedure. Depend upon whether the micro particles are to ye used exclusively on animal research or for diagnostic and therapeutic purposes the potential biocompatability of the particular type ox microparticl~ is a s~nl~cant consideration.
The metal-containing micr~pax~icles of the prevent invention are e~ho~enic (Joe., capable of reflecting sound wives being composed of material having acoustic properties which are significantly different from those of blood or Tess Their size is small enough to permit their passage through capillax~es 9 if Nasser without being filtered out prior to reaching the area to ye imaged ego. 8 where a peripheral venous injection site is used; husk they will by capable of perfusing tissue and producing an enhanced image of the tl~sue, organ and any diffe~ntlation between well-perfused and poorly-perfused tissue, wltho~-t being iniquity into the arteries or directly into the area to be imaged Thus, they may be injected into a peripheral vain or other predetermined area of the body resulting in considerably lets invasion than the arterial injections required for on angiogram~
In addition, unlike any of the gaseous bubbles known to the prior art the metal-containing micro particles of the present invention are quan~if~ably reproducible 7. PD6506 Further, use of microparti~les as a contrast agent does no require machinery which is as sophisticated or expensive as that required by radio-nuclide imaging, nor does their use require exposure to radioactive materials Thus, while overcoming many of the problems associated with the prior art, the present invention makes possible the production of unique images of various organ systems. although the invention technique it applicable Jo various animal and human Cody organ systems, its novel features and advantages may be better understood from the following description of it use in obtaining image of myocardial tissue and perfusion or blood flow patterns The description and accompanying drawing are included for purposes of illustration only, it being expressly understood that they are not intended to be a definition of the limits ox the invention D
In reviewing the description and drawings it should be kept in mind that the heart is a pump fed by many blood vessels which, during the course of time, may become partlall~ or totally blocked, causing damage to the heart tissue. In the past, information concerning the state of the blood vessels was primarily obtained through the involve angiog~aphy techniques described above or through surgery. on addition information concerning the heart tls~u~ was opined using radio-knucklehead imaging or surgery; the angiogram produced no direct data r2gardiny the tissue but rather required the drawing of inferences from data obtained with respect 3Q to the major blood vessels and wall motions of the heart.
I
8. PD6506 BRIEF DESCRIPTION OF TOE DRAWINGS
The invention will now be described with reference to the accompanying drawing, wherein:
FIGURE 1 is a schematic view showing the use of an ultrasonic scanner in echo cardiography; and FIGURES 2~5 are cross sectional images of the heart enhanced by the use of contrast agents flowing there through.
owe 9. PD6506 DETAINED DESCRIPTION OF TOE INVENTION
FIGURE 1 Is a schematic view of the heart and lungs, as well as of ultrasonic scanning equipment consisting of a scanner lo and imaging apparatus 12, The equipment produces visual images of a predetermined area, in this case, the heart region of a human Cody. Typically, the scanner lo is placed directly on the skin lo over the area to be mud 16~ The scanner 10 houses various electronic components including ultrasonic transducers.
lo The spanner lo produces ultrasonic waves 18 which perform a sector scan of the Lear region 16~ The ultrasonic waves lo are reflexed by the various portions of the heart region 16 and are received by the generating transducer and processed in accordance wow pulse-echo methods known on the art. After processing 7 signals are sent to the immune apparatus 12 (also well known in the art for viewing.
In the method of the present invention, after the patient is Warped" and the scanner lo it in place, the sonicated microbubbl~ or micro particle contrast agent it injected for example t through an arm vein r generally indicated at 24. The contrast agent flow through the vein 24 in the direction of the arrow 26~
through the fight (venous wide 28 ox the heart 30 p through the main pulmonary artery 29 leading to the lungs 32, across the lungs 32~ through the coupler 34 t into the pulmonary veins 35 and finally unto the left atrium 36 and the left ventricular cavity 37 of top heart 30.
The present invention is directed to both son~cated micro bubbles and microparti~ulate matter used as contrast agents. It has been found thaw the use of socketed micro bubbles or solid micro particulate matter such as glass or graphite produce images hiving vividly contrasting areas O particular r such ~icroparticles (lo are solid OX semi~5011dp to do not contain trapped air, I may be biocompatlble or biodegradable, I are I
I P~506 small enough to pass through the capillary buds which are about 8 to 10 microns in size, and (I have acoustic properties maying them echogenic. While not to be bound by any theory, both the sonicated micro bubbles and the micro particles of the present invention produce ~otlceably clearer and more detailed images of the myocardial tissue and microvasculature~ a compared with prior art contrast agent Referring now to FIGURES 2-5 J one can see con fast echocardiogra~ produced by the ut.tlizatio~ of the ssnicated micro bubble keenest agent of the present invention In the figures a horseshoe-~haped portion 50 represents the left ventricular wall muscle (or tissue) which encloses the left ventricular cavity 37. The ~icrobubbles were injected into the pulmonary artery of a dog and have roused the capillary beds of the lung Jo enter the let atrium 36 and the left ventricular cavity 37 unto the aorta through the coronary arteries and eventually unto the loft ventricular Tao 50 enhancing the image thereof.
Specifically, FIGURE 2 owe a two-dimensional ech3cardiogram ED image of the left ventricular suavity 37 and loft atrium 36, prior to the introduction of the ~onicated micro bubbles FIGURE 3 illustrates the injection of a 10 my sonicated Renografin~aCl mixture through a wedged pulmonary artery coauthor us Jan be seen the contrast agent appears in the left atrium 36 and flow into the left ventricle 379 In FIGURE 4, substantially complete opacity of the left ventricular cavity 37 has oc~urredD In FOE 5, subsequent pacification of the myocardial tissue 50 can be seen This is buckeyes the blood carrying the contrast agent has flowed through the aorta into the coronary arteries which supply toe blood to the ~yocardial tissue 50. Thus observations and diagnoses can be made with respect to the amount of tome required for thy brood to pass through the lungs, blood flow patterns, --.11~
1 the size of the left atrium, the competence of the mitral valve (which separates the left atrium and left ventricle, chamber dimensions on the left ventricular cavity and wall motion abnormalities. Upon ejector of the contrast agent from the left ventricle, the competence owe the aorta valve also may be analyzed, as well as the ejection fraction or percentage of volume ejected from the effete ventricle. Finally, the contrast patterns in the tissue will indicate which areas, if any, are not being adequately perfused.
In summary, such a pattern of images will help diagnose unusual blood flow characteristics within the heart, valvular competence, chamber sizes and wall motion, and will provide a potential indicator of myocardial perfusion.
In the example set forth above, the micro bubbles were produced from a mixture of Renogra~in~6 (a relatively non-toxic, biocompatable radio-opaque dye well known in the art) and saline in a one-to-one ratio. This mixture was sonicated, i.e.
subjected to high frequency energy, for about 30 seconds by a Heat System 375 watt sonicator. Such sonicators are well known in the art for other uses, and usually emit ultrasonic energy of 20,000 Ho, although energies of 5,000 to 30,000 Ho or even higher are within the scope of the-present invention Depending on the contrast agent selected, such as the mixture described above, sugar solutions or the like, varying bubble sizes are produced, usually however/ within the desired range of about 6 to 20 microns in diameter Besides the scanner 10 briefly described above, there exist other ultrasonic scanners, examples of which are disclosed in US. Patent Nos. 4,143,554 and 4,315,435. basically, these patents relate to various techniques including dynamic cross-sectional echography (DOE) for producing sequential two-dimensional images I P~6506 of cross-sectlonal slices of the animal or human anatomy by means of ultrasound energy at a frame rate sufficient to enable dynamic visualization of moving organs Types of apparatus u illzed in DOE are generally called DOE
scanners and transmit and receive short, sonic pulses in the form of narrow beams or lines The reflected s~gnalsl strength is a junction of time, which is converted to a position using a nominal wound speed and is displayed on a cathode ray tube or other suitable device on a manner somewhat analogous to radar or sonar displays. Whole DO can be used to produce image of many organ systems including the lover, gall bladder t pancreas and kidney it it frequently used for visualization of tissue and major blood vessel of the heart misting DOE scanners car be classified according to the geometry of their field of view (linear or sector scanning)/ according to the means used for scanning that field of view (mechanical or electronic scanning) 20 and according to ether the trar~sdu~er scan the patient or object thrc3ugh an intervening water bath or by direct corltact Waco the Sirius of the object a, for example the skin of a patient using an appropriate contact gel or oil. Linear scanner produce a scan of the anatomy 25 consisting of a jet so nominally parallel scan line I, displaced with respect 'co one another by a fine spacing roughly cornpara~le to the effects width of each llneg as detQxmined primarily by the trouncers used on the apparatus. the cross sectiorl imaged by such scanners 30 it therefore approximately rectangular in shape, its width being determined by the line spacing and total number ox line, while its depth is determined by the penetrations range of 'eke ultrasound energy into the Tao. Linear scanrlers are generally used where there 35 is a relatively extended region of shop body surface from which access to the part of interest of the anatomy I possible, such a in to abdominal orison 13. PD~506 Sector scanners produce a scan of the anatomy consisting of a fan of divergent lines spaced angularly from one another, but intersecting nominally) at a point. The angular spacing is even or uneven depending upon the apparatus, and is roughly comparable to the effective angular width of each fine. Sector scanners are generally used where the anatomical window or region of the body surface from which access Jo the anatomical part of intones is relatively small, as in the adult hear, the brain and the eye Another type of sector scanner is mechanical in nature and can be further divided into two subleases, oscillating transducer scanners and wrung transducer swooners An oscillating transducer spanner us one in which a single transducer is oscillated about an axis nominally lined in the front plane and pausing through the center of the transducer with an appropriate angle sensor being used to-monitor the angular position of the transducer at any time. In a typical rotating transducer scanner, several transducer spin inside a small do filled Wylie liquid, with one transducer at a iamb scanning the area of interest. These and other scanners are within the. scope of the present invention.
As squatted above r in attempting to find a safe, 25 reproducible, quantify table contrast agent for use in producing an enhanced ultrasonic image of the tissue under study, researches have used saccharine arid gelatin encapsulated micro bubbles of nltro~en or carbon dioxide gas having a mean size of approximately 75 micron, 30 pressurized gas Ida liquids (e.g. ~22~ 7 aid a~echanlcally agitated (hand shaken) mixtllres of Lowe d solution Ever, wince the pulmonary artery coupler are about 8 to 10 microns in do ampler the 75 micron encapsulated micro bubbles may not cross the capillary US bets and, as a royalty their us would require a direct in section unto the area to be imaged or an crier tat injection involving the same xlsk a the invasive 14~ PD6506 approach of angiography discussed above. Further, micro bubbles produced by agitating various liquids owner than by sonicating Tom) have wide variability of size.
Variable amount of such non-encapsulated aglta~ed micro bubbles can pass through capillaries, but the present state of the art has only produced qualitative data due to the inability to control the variable described above. These contrast agent all work to some degree, but suffer from 2 number of problems including the fact that the size of the bubbles is not uniform Those and other problems are overcome by the ~onicated micro bubbles of the present invention.
However, while son axed microbubblPs are more uniform in size and produce enhanced images, the lo potential problem associated with the introduct~n of air remain The danker of injecting microbubblesO
encapsulated or not into the heart is thaw the bubbles eventually collapse and the amount of dissolved elf may be toxic in the arterial stem ego., of the brain and 20 kidneys) a well a in other micro circulatory system Thus it it evident that the particular contrast agent selected will depend upon the purpose of the imaging or expel an aunts potential risk factors should be considered for diagno~ic or ~herapeutlc use the size of the contrast material I also of concern, If the particles are too large they will not past through the capillaries and thus ~111 require direct or ayatollah injec~lons if the aria to be imaged lies beyond the c~p;llar;esO On the other hand d of the contrast agent is zoo small, it may not wreck sound waves emitted by the ultrasonic transducer.
idea particulate matter which produces contrast-type enhanced images include graphite particles, lass beads, and similar substances. The present inanity Or has grossly examined many of the available solid particulate matter which theoretically may be used as a contrast agent t and has determined that one such agent, -15~ ~2~7~
1 although no-t previously disclosed as a contrast yenta has a number of very desirable properties. Such agent and associated liquid carriers are broadly disclosed in US. Patent No.
4,247,4~6. In the '406 patent, the solid particulate material comprises magnetically localizable, biodegradable carriers which comprise micro spheres formed from an amino acid polymer matrix with magnetic particles embedded therein. For example, albumin can be used as the matrix material and magnetize (Foe) can be used as the magnetic particles. The micro spheres have an average diameter of less than 1.5 microns and the magnetic particles contained therein have an average size of not more than 1,000 Angstroms. The micro spheres may contain from 50 to 350 parts by weight of the magnetic material per 100 parts of the amino acid polymer. The mierospheres may contain the magnetic particles uniformly distributed throughout the matrix, or, preferably, may be concentrated in the peripheral portions.
Other particles having similar characteristics are also within the scope of the present invention.
By the use of these specifically defined metal containing solid contrast agents, echo cardiograms having the desired resolution may be produced Further since the micro particles described above are biodegradable, their side effects are minimized.
The mieropartieles may be used for imaging a wide variety of areas, even when injected at a peripheral venous site.
Those areas include (without limitation): (1) the venous drainage system to the heart; I the myocardial tissue and perfusion characteristics during an exercise treadmill test or the like, and I myocardial tissue after an oral ingestion or intravenous injection of drugs designed to increase blood flow to the tissue.
Additionally, the micro particles may be useful in delineating changes in the myocardial tissue 16~ PD~506 perfusion due to interventions such as: I coronary artery vein grafting; 2) coronary artery angioplasty (balloon dilatation of a narrowed artery); 3) use of thrombolytic agents such as s~rep~okinse) to dissolve clots in coronary arteries; or 4) perfusion defects or changes due to recent heart attack.
Furthermore r at the time of a coronary angiogram (or a digital subtraction angiogram~ an injection of the micro particles may provide data with respect to tissue perfusion characteristics what would augment and complement the data obtained from the angiogram procedure, which identifies only the anatomy of the blood vessels Through the use of the micro particles of the present invention, other non cardiac organ systems including without limitation the liver spleen, kidney, etch that are presently imaged by ultrasonic techniques may be susceptible to an enhancement of such currently obtainable images, Andre the generation of new images showing perfusion and flow characteristics thaw had not previously been susceptible to imaging Using prior art ultrasonic imaging techniques In terms Jo method of operation, the use of the subject micro particle would be the Same as aye described bye with respect to gonica~ed micro bubbles. The amount of micropar~icles used would be defendant ox a number of factors lnclu~ing the choice of liquid carriers (water, sugar solution, etch degree of opacity dullard areas of the body to be imaged, site of injection and number of injections In all instances, however, sufficient m~cropart;~les would be used in the liquid carrier o achieve discernible images by the use of ultrasonic scanning.
Having described the invention, it is obvious thaw other modifications may be made by those skilled in the art. or example, other water soluble polymers can be used in place ox albumin lnclud~ng hemoglobin and other magnetic particles can be used in place of magnetites 17~ PD6506 etc., including magnetic iron oxides, carbonyl iron and the like. This invention, therefore, is to be limited only to the scope and spirit of the appended claims.
The contrast agents themselves are intense sound wave reflectors because of the acoustic difference between the liquid and the gas micro bubbles dissolved therein; thus, when the contrast agents are netted into and perfuse the microvasculature of tissue clearer images of such tissue may be produced however, notwithstanding the use I such contrast agents, the image produced for example of the myocardial tissue, is of relatively poor quality; is highly variable and is not quantifiable due to the variable size and persistence associated with prior art micro bubble Further, the problems of air embolism toxicity have not .
yet been investigated 3r3 SPRY OF THE INVENTION
One embodiment of the present invention is directed to an improvement associated with such prior art contrast agents by which smaller and more uniform micro bubbles are produced. A second embodiment is directed to the novel use of specifically defined metal-containing solid or semisolid contrast agents.
The Conrad agents of the present invention are I echogenic (i.e., capable ox reflecting sound waves), I small enough to pass through capillaries so as to perfuse tissue previously lnacces~ible to the prior art contrast agent injected into a peripheral venous site thereby producing enhanced image of such tissue and organs and permitting differentiation between well-perfused and poorly-perfused tissue, and (3) quantiflably reproducible In addition the metal-containlng solid or semi-solid contrast agents of the present invention are tree of the potential air embolism toxicity risks associated with the introduction of gaseous bubbles into the human or animal septum It no believed that such particulate matter has ever been used as a contrast agent in medical proceeder The method of the present inYe~tion (1) permits the imaging of organ systems which could not be imaged using prior art ultrasonic technique 7 and I permits clearer, more detailed imaging of certain area which were Lubell using such prior art techniques.
In the first embodiment of the preset invention, a viscous solution ego, 70% Dextrose 50% Dextrose, 70~ orbital Renogratin-76~ mixtures of these agents, and the like) is subjected to high frequency (Roy to Tao Ho) ultra only energy. As a royalty mierobubbles having a diameter of approximately 6 to 20 microns are produced. For ease of reference such micro bubble will be referred to herein as ~sonicated" micr~bubble~. As described in greater detail hereinbelow, such sonicated I
I PD65~6 micro bubbles have been found to be Improved con~ra5t agents .
The second embodiment of the present invention is directed to selected metal-containing micropartlcle~
used as contrast agents to reflect intense patterns of sound waves The contrast agents of the present invention are detected by conventional ultrasonic scanning equipment and translated into images in the manner described above.
The use of the microp~rticles it especially advantageous in that it orates the nerd to introduce gaseous bubbles as contrast agents in the human or animal Siam, and thus eliminates the air embolism toxicity risk inherent in that procedure. Depend upon whether the micro particles are to ye used exclusively on animal research or for diagnostic and therapeutic purposes the potential biocompatability of the particular type ox microparticl~ is a s~nl~cant consideration.
The metal-containing micr~pax~icles of the prevent invention are e~ho~enic (Joe., capable of reflecting sound wives being composed of material having acoustic properties which are significantly different from those of blood or Tess Their size is small enough to permit their passage through capillax~es 9 if Nasser without being filtered out prior to reaching the area to ye imaged ego. 8 where a peripheral venous injection site is used; husk they will by capable of perfusing tissue and producing an enhanced image of the tl~sue, organ and any diffe~ntlation between well-perfused and poorly-perfused tissue, wltho~-t being iniquity into the arteries or directly into the area to be imaged Thus, they may be injected into a peripheral vain or other predetermined area of the body resulting in considerably lets invasion than the arterial injections required for on angiogram~
In addition, unlike any of the gaseous bubbles known to the prior art the metal-containing micro particles of the present invention are quan~if~ably reproducible 7. PD6506 Further, use of microparti~les as a contrast agent does no require machinery which is as sophisticated or expensive as that required by radio-nuclide imaging, nor does their use require exposure to radioactive materials Thus, while overcoming many of the problems associated with the prior art, the present invention makes possible the production of unique images of various organ systems. although the invention technique it applicable Jo various animal and human Cody organ systems, its novel features and advantages may be better understood from the following description of it use in obtaining image of myocardial tissue and perfusion or blood flow patterns The description and accompanying drawing are included for purposes of illustration only, it being expressly understood that they are not intended to be a definition of the limits ox the invention D
In reviewing the description and drawings it should be kept in mind that the heart is a pump fed by many blood vessels which, during the course of time, may become partlall~ or totally blocked, causing damage to the heart tissue. In the past, information concerning the state of the blood vessels was primarily obtained through the involve angiog~aphy techniques described above or through surgery. on addition information concerning the heart tls~u~ was opined using radio-knucklehead imaging or surgery; the angiogram produced no direct data r2gardiny the tissue but rather required the drawing of inferences from data obtained with respect 3Q to the major blood vessels and wall motions of the heart.
I
8. PD6506 BRIEF DESCRIPTION OF TOE DRAWINGS
The invention will now be described with reference to the accompanying drawing, wherein:
FIGURE 1 is a schematic view showing the use of an ultrasonic scanner in echo cardiography; and FIGURES 2~5 are cross sectional images of the heart enhanced by the use of contrast agents flowing there through.
owe 9. PD6506 DETAINED DESCRIPTION OF TOE INVENTION
FIGURE 1 Is a schematic view of the heart and lungs, as well as of ultrasonic scanning equipment consisting of a scanner lo and imaging apparatus 12, The equipment produces visual images of a predetermined area, in this case, the heart region of a human Cody. Typically, the scanner lo is placed directly on the skin lo over the area to be mud 16~ The scanner 10 houses various electronic components including ultrasonic transducers.
lo The spanner lo produces ultrasonic waves 18 which perform a sector scan of the Lear region 16~ The ultrasonic waves lo are reflexed by the various portions of the heart region 16 and are received by the generating transducer and processed in accordance wow pulse-echo methods known on the art. After processing 7 signals are sent to the immune apparatus 12 (also well known in the art for viewing.
In the method of the present invention, after the patient is Warped" and the scanner lo it in place, the sonicated microbubbl~ or micro particle contrast agent it injected for example t through an arm vein r generally indicated at 24. The contrast agent flow through the vein 24 in the direction of the arrow 26~
through the fight (venous wide 28 ox the heart 30 p through the main pulmonary artery 29 leading to the lungs 32, across the lungs 32~ through the coupler 34 t into the pulmonary veins 35 and finally unto the left atrium 36 and the left ventricular cavity 37 of top heart 30.
The present invention is directed to both son~cated micro bubbles and microparti~ulate matter used as contrast agents. It has been found thaw the use of socketed micro bubbles or solid micro particulate matter such as glass or graphite produce images hiving vividly contrasting areas O particular r such ~icroparticles (lo are solid OX semi~5011dp to do not contain trapped air, I may be biocompatlble or biodegradable, I are I
I P~506 small enough to pass through the capillary buds which are about 8 to 10 microns in size, and (I have acoustic properties maying them echogenic. While not to be bound by any theory, both the sonicated micro bubbles and the micro particles of the present invention produce ~otlceably clearer and more detailed images of the myocardial tissue and microvasculature~ a compared with prior art contrast agent Referring now to FIGURES 2-5 J one can see con fast echocardiogra~ produced by the ut.tlizatio~ of the ssnicated micro bubble keenest agent of the present invention In the figures a horseshoe-~haped portion 50 represents the left ventricular wall muscle (or tissue) which encloses the left ventricular cavity 37. The ~icrobubbles were injected into the pulmonary artery of a dog and have roused the capillary beds of the lung Jo enter the let atrium 36 and the left ventricular cavity 37 unto the aorta through the coronary arteries and eventually unto the loft ventricular Tao 50 enhancing the image thereof.
Specifically, FIGURE 2 owe a two-dimensional ech3cardiogram ED image of the left ventricular suavity 37 and loft atrium 36, prior to the introduction of the ~onicated micro bubbles FIGURE 3 illustrates the injection of a 10 my sonicated Renografin~aCl mixture through a wedged pulmonary artery coauthor us Jan be seen the contrast agent appears in the left atrium 36 and flow into the left ventricle 379 In FIGURE 4, substantially complete opacity of the left ventricular cavity 37 has oc~urredD In FOE 5, subsequent pacification of the myocardial tissue 50 can be seen This is buckeyes the blood carrying the contrast agent has flowed through the aorta into the coronary arteries which supply toe blood to the ~yocardial tissue 50. Thus observations and diagnoses can be made with respect to the amount of tome required for thy brood to pass through the lungs, blood flow patterns, --.11~
1 the size of the left atrium, the competence of the mitral valve (which separates the left atrium and left ventricle, chamber dimensions on the left ventricular cavity and wall motion abnormalities. Upon ejector of the contrast agent from the left ventricle, the competence owe the aorta valve also may be analyzed, as well as the ejection fraction or percentage of volume ejected from the effete ventricle. Finally, the contrast patterns in the tissue will indicate which areas, if any, are not being adequately perfused.
In summary, such a pattern of images will help diagnose unusual blood flow characteristics within the heart, valvular competence, chamber sizes and wall motion, and will provide a potential indicator of myocardial perfusion.
In the example set forth above, the micro bubbles were produced from a mixture of Renogra~in~6 (a relatively non-toxic, biocompatable radio-opaque dye well known in the art) and saline in a one-to-one ratio. This mixture was sonicated, i.e.
subjected to high frequency energy, for about 30 seconds by a Heat System 375 watt sonicator. Such sonicators are well known in the art for other uses, and usually emit ultrasonic energy of 20,000 Ho, although energies of 5,000 to 30,000 Ho or even higher are within the scope of the-present invention Depending on the contrast agent selected, such as the mixture described above, sugar solutions or the like, varying bubble sizes are produced, usually however/ within the desired range of about 6 to 20 microns in diameter Besides the scanner 10 briefly described above, there exist other ultrasonic scanners, examples of which are disclosed in US. Patent Nos. 4,143,554 and 4,315,435. basically, these patents relate to various techniques including dynamic cross-sectional echography (DOE) for producing sequential two-dimensional images I P~6506 of cross-sectlonal slices of the animal or human anatomy by means of ultrasound energy at a frame rate sufficient to enable dynamic visualization of moving organs Types of apparatus u illzed in DOE are generally called DOE
scanners and transmit and receive short, sonic pulses in the form of narrow beams or lines The reflected s~gnalsl strength is a junction of time, which is converted to a position using a nominal wound speed and is displayed on a cathode ray tube or other suitable device on a manner somewhat analogous to radar or sonar displays. Whole DO can be used to produce image of many organ systems including the lover, gall bladder t pancreas and kidney it it frequently used for visualization of tissue and major blood vessel of the heart misting DOE scanners car be classified according to the geometry of their field of view (linear or sector scanning)/ according to the means used for scanning that field of view (mechanical or electronic scanning) 20 and according to ether the trar~sdu~er scan the patient or object thrc3ugh an intervening water bath or by direct corltact Waco the Sirius of the object a, for example the skin of a patient using an appropriate contact gel or oil. Linear scanner produce a scan of the anatomy 25 consisting of a jet so nominally parallel scan line I, displaced with respect 'co one another by a fine spacing roughly cornpara~le to the effects width of each llneg as detQxmined primarily by the trouncers used on the apparatus. the cross sectiorl imaged by such scanners 30 it therefore approximately rectangular in shape, its width being determined by the line spacing and total number ox line, while its depth is determined by the penetrations range of 'eke ultrasound energy into the Tao. Linear scanrlers are generally used where there 35 is a relatively extended region of shop body surface from which access to the part of interest of the anatomy I possible, such a in to abdominal orison 13. PD~506 Sector scanners produce a scan of the anatomy consisting of a fan of divergent lines spaced angularly from one another, but intersecting nominally) at a point. The angular spacing is even or uneven depending upon the apparatus, and is roughly comparable to the effective angular width of each fine. Sector scanners are generally used where the anatomical window or region of the body surface from which access Jo the anatomical part of intones is relatively small, as in the adult hear, the brain and the eye Another type of sector scanner is mechanical in nature and can be further divided into two subleases, oscillating transducer scanners and wrung transducer swooners An oscillating transducer spanner us one in which a single transducer is oscillated about an axis nominally lined in the front plane and pausing through the center of the transducer with an appropriate angle sensor being used to-monitor the angular position of the transducer at any time. In a typical rotating transducer scanner, several transducer spin inside a small do filled Wylie liquid, with one transducer at a iamb scanning the area of interest. These and other scanners are within the. scope of the present invention.
As squatted above r in attempting to find a safe, 25 reproducible, quantify table contrast agent for use in producing an enhanced ultrasonic image of the tissue under study, researches have used saccharine arid gelatin encapsulated micro bubbles of nltro~en or carbon dioxide gas having a mean size of approximately 75 micron, 30 pressurized gas Ida liquids (e.g. ~22~ 7 aid a~echanlcally agitated (hand shaken) mixtllres of Lowe d solution Ever, wince the pulmonary artery coupler are about 8 to 10 microns in do ampler the 75 micron encapsulated micro bubbles may not cross the capillary US bets and, as a royalty their us would require a direct in section unto the area to be imaged or an crier tat injection involving the same xlsk a the invasive 14~ PD6506 approach of angiography discussed above. Further, micro bubbles produced by agitating various liquids owner than by sonicating Tom) have wide variability of size.
Variable amount of such non-encapsulated aglta~ed micro bubbles can pass through capillaries, but the present state of the art has only produced qualitative data due to the inability to control the variable described above. These contrast agent all work to some degree, but suffer from 2 number of problems including the fact that the size of the bubbles is not uniform Those and other problems are overcome by the ~onicated micro bubbles of the present invention.
However, while son axed microbubblPs are more uniform in size and produce enhanced images, the lo potential problem associated with the introduct~n of air remain The danker of injecting microbubblesO
encapsulated or not into the heart is thaw the bubbles eventually collapse and the amount of dissolved elf may be toxic in the arterial stem ego., of the brain and 20 kidneys) a well a in other micro circulatory system Thus it it evident that the particular contrast agent selected will depend upon the purpose of the imaging or expel an aunts potential risk factors should be considered for diagno~ic or ~herapeutlc use the size of the contrast material I also of concern, If the particles are too large they will not past through the capillaries and thus ~111 require direct or ayatollah injec~lons if the aria to be imaged lies beyond the c~p;llar;esO On the other hand d of the contrast agent is zoo small, it may not wreck sound waves emitted by the ultrasonic transducer.
idea particulate matter which produces contrast-type enhanced images include graphite particles, lass beads, and similar substances. The present inanity Or has grossly examined many of the available solid particulate matter which theoretically may be used as a contrast agent t and has determined that one such agent, -15~ ~2~7~
1 although no-t previously disclosed as a contrast yenta has a number of very desirable properties. Such agent and associated liquid carriers are broadly disclosed in US. Patent No.
4,247,4~6. In the '406 patent, the solid particulate material comprises magnetically localizable, biodegradable carriers which comprise micro spheres formed from an amino acid polymer matrix with magnetic particles embedded therein. For example, albumin can be used as the matrix material and magnetize (Foe) can be used as the magnetic particles. The micro spheres have an average diameter of less than 1.5 microns and the magnetic particles contained therein have an average size of not more than 1,000 Angstroms. The micro spheres may contain from 50 to 350 parts by weight of the magnetic material per 100 parts of the amino acid polymer. The mierospheres may contain the magnetic particles uniformly distributed throughout the matrix, or, preferably, may be concentrated in the peripheral portions.
Other particles having similar characteristics are also within the scope of the present invention.
By the use of these specifically defined metal containing solid contrast agents, echo cardiograms having the desired resolution may be produced Further since the micro particles described above are biodegradable, their side effects are minimized.
The mieropartieles may be used for imaging a wide variety of areas, even when injected at a peripheral venous site.
Those areas include (without limitation): (1) the venous drainage system to the heart; I the myocardial tissue and perfusion characteristics during an exercise treadmill test or the like, and I myocardial tissue after an oral ingestion or intravenous injection of drugs designed to increase blood flow to the tissue.
Additionally, the micro particles may be useful in delineating changes in the myocardial tissue 16~ PD~506 perfusion due to interventions such as: I coronary artery vein grafting; 2) coronary artery angioplasty (balloon dilatation of a narrowed artery); 3) use of thrombolytic agents such as s~rep~okinse) to dissolve clots in coronary arteries; or 4) perfusion defects or changes due to recent heart attack.
Furthermore r at the time of a coronary angiogram (or a digital subtraction angiogram~ an injection of the micro particles may provide data with respect to tissue perfusion characteristics what would augment and complement the data obtained from the angiogram procedure, which identifies only the anatomy of the blood vessels Through the use of the micro particles of the present invention, other non cardiac organ systems including without limitation the liver spleen, kidney, etch that are presently imaged by ultrasonic techniques may be susceptible to an enhancement of such currently obtainable images, Andre the generation of new images showing perfusion and flow characteristics thaw had not previously been susceptible to imaging Using prior art ultrasonic imaging techniques In terms Jo method of operation, the use of the subject micro particle would be the Same as aye described bye with respect to gonica~ed micro bubbles. The amount of micropar~icles used would be defendant ox a number of factors lnclu~ing the choice of liquid carriers (water, sugar solution, etch degree of opacity dullard areas of the body to be imaged, site of injection and number of injections In all instances, however, sufficient m~cropart;~les would be used in the liquid carrier o achieve discernible images by the use of ultrasonic scanning.
Having described the invention, it is obvious thaw other modifications may be made by those skilled in the art. or example, other water soluble polymers can be used in place ox albumin lnclud~ng hemoglobin and other magnetic particles can be used in place of magnetites 17~ PD6506 etc., including magnetic iron oxides, carbonyl iron and the like. This invention, therefore, is to be limited only to the scope and spirit of the appended claims.
Claims (22)
- CLAIM 1 A method of ultrasonic imaging for use in medical procedures, comprising the steps of:
(a) injecting biodegradable, metal-containing microparticles into a mammal to thereby alter the acoustic properties of a predetermined area; and (b) ultrasonically scanning an area including said predetermined area so as to obtain an image of said predetermined area. - CLAIM 2 The method according to Claim 1 wherein said microparticles have an average diameter of less than 1.5 microns and are formed from an amino acid polymer matrix with magnetic iron particles embedded therein, said magnetic particles have an average size of not more than 1,000 Angstroms.
- CLAIM 3 The method according to Claim 1 wherein said predetermined area comprises the heart.
- CLAIM 4 The method according to Claim 1 wherein said microparticles are injected into the coronary arteries.
- CLAIM 5 The method according to Claim 1 wherein said microparticles are injected into the peripheral veneous system.
- CLAIM 6 The method according to Claim 1 wherein, in lieu of said biodegradable microparticles, biocompatible microparticles are used.
19. - CLAIM 7 A method of ultrasonic imaging for use in medical procedures, comprising the steps of:
(a) subjecting a biocompatible liquid to high frequency energy in the range of about 5,000 to 30,000 Hz so as to produce microbubbles having substantially uniform diameter;
(b) injecting said microbubbles into a mammal to thereby alter the acoustic properties of a predetermined area; and (c) ultrasonically scanning an area including said predetermined area so as to obtain an enhanced image of said predetermined area. - CLAIM 8 The method according to Claim 7 wherein said microbubbles have a mean particle size of about 6 to 20 microns.
- CLAIM 9 The method according to Claim 7 wherein said liquid is subjected to high frequency energy of about 20,000 Hz.
- 10. A method of ultrasonic imaging for use in medical procedures, comprising the steps of:
a) forming biocompatible microparticles comprising amino acid polymer matrix containing at least one ultrasound image enhancing material selected from the group consisting of glass, graphite, magnetic particles, magnetite, magnetic iron oxides and carbonyl iron;
b) injecting said microparticles into a mammal to thereby alter the acoustic properties of a predetermined area; and c) ultrasonically scanning said predetermined area to obtain an ultrasound scanning image thereof. - 11. The method of Claim 7 wherein said biocompatible liquid is a viscous solution.
- 12. The method of Claim 11 wherein said viscous solution is selected from the group consisting of dextrose, sorbitol, relatively nontoxic radio-opaque dye, and mixtures thereof.
- 13. The method of Claim 12 further comprising saline as a diluent.
- 14. The method of Claim 11 wherein said viscous solution is a mixture of relatively non-toxic radio-opaque dye and sodium chloride.
- 15. The method of Claim 7 wherein the step of subjecting said biocompatible liquid to high frequency energy results in cavitation bubbles and said cavitation bubbles collapse resulting in by-product bubbles having substantially uniform diameter.
- 16. A method of ultrasound imaging for use in medical procedures, comprising the steps of:
a) subjecting a biocompatible liquid to high frequency ultrasound energy in the range of about 5,000 to 30,000 Hz thereby producing stable microbubbles having substantially uniform diameters in the range of 6 to 20 microns;
(b) injecting said microbubbles into a mammal to thereby alter the acoustic properties of a predetermined area thereof: and c) ultrasonically scanning an area including said predetermined area so as to obtain an enhanced image of said predetermined area. - 17. A method of ultrasound imaging for use in medical procedures, comprising the steps of:
(a) providing a biocompatible liquid selected from the group consisting of dextrose, sorbitol, relatively non-toxic radio-opaque dye and mixtures thereof;
(b) subjecting said biocompatible liquid to ultrasound energy in the range of 5,000 to 30,000 Hz thereby producing stable microbubbles having substantially uniform diameters in the range of 6 to 20 microns;
c) injecting said microbubbles into a mammal to thereby alter the acoustic properties of a predetermined area of said mammal; and (d) ultrasonically scanning said mammal including said predetermined area thereby obtaining enhanced images of said predetermined area. - 18. The method of Claim 17 wherein said biocompatible liquid is selected from the group consisting of 70% dextrose, 50% dextrose, 70% sorbitol, a non-toxic radio-opaque dye, and mixtures thereof.
- 19. The method of Claim 17 wherein said biocompatible liquid further comprises saline.
- 20. A contrast agent for diagnostic ultrasound imaging of organs in mammals comprising a biocompatible liquid containing stable microbubbles of substantially uniform diameters in the range of 6 to 20 microns, said microbubbles having been produced by subjecting the liquid to high frequency ultrasound energy in the range of 5,000 to 30,000 Hz.
- 21. The contrast agent of Claim 20 wherein said liquid comprises a viscous solution selected from the group consisting of dextrose, sorbitol, non-toxic radio opaque dye, and mixtures thereof.
- 22. A method of ultrasonic imaging for use in medical procedures, comprising the steps of:
a) forming biocompatible microparticles com-prising amino acid polymer matrix containing at least one ulstrasound image enhancing material selected from the group consisting of air, glass, graphite, nitrogen, carbon dioxide, magnetic particles, magnetite, magnetic iron oxides and carbonyl iron;
b) injecting said microparticles into a mammal to thereby alter the acoustic properties of a predetermined area; and c) ultrasonically scanning said predetermined area to obtain an ultrasound scanning image thereof.
What is claimed is:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/461,664 US4572203A (en) | 1983-01-27 | 1983-01-27 | Contact agents for ultrasonic imaging |
US461,664 | 1983-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1221759A true CA1221759A (en) | 1987-05-12 |
Family
ID=23833459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000446243A Expired CA1221759A (en) | 1983-01-27 | 1984-01-27 | Ultrasonic imaging technique |
Country Status (13)
Country | Link |
---|---|
US (1) | US4572203A (en) |
EP (1) | EP0135563B1 (en) |
JP (1) | JPS60500486A (en) |
AT (1) | AT397034B (en) |
AU (1) | AU571863B2 (en) |
CA (1) | CA1221759A (en) |
DE (1) | DE3490013T1 (en) |
FR (1) | FR2541108B1 (en) |
GB (1) | GB2143327B (en) |
IL (1) | IL70784A (en) |
NL (1) | NL191079C (en) |
SE (1) | SE466634B (en) |
WO (1) | WO1984002838A1 (en) |
Families Citing this family (218)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681119A (en) * | 1980-11-17 | 1987-07-21 | Schering Aktiengesellschaft | Method of production and use of microbubble precursors |
US4718433A (en) * | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
US5141738A (en) * | 1983-04-15 | 1992-08-25 | Schering Aktiengesellschaft | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof |
SE463651B (en) * | 1983-12-21 | 1991-01-07 | Nycomed As | DIAGNOSTIC AND CONTRACTOR |
US6203777B1 (en) * | 1983-12-21 | 2001-03-20 | Nycomed Imaging As | Method of contrast enhanced magnetic resonance imaging using carbohydrate particles |
US5618514A (en) * | 1983-12-21 | 1997-04-08 | Nycomed Imaging As | Diagnostic and contrast agent |
US5599296A (en) * | 1991-02-14 | 1997-02-04 | Wayne State University | Apparatus and method of delivery of gas-supersaturated liquids |
US5261875A (en) * | 1991-02-14 | 1993-11-16 | Wayne State University | Method and apparatus for injection of gas hydrates |
DE3529195A1 (en) * | 1985-08-14 | 1987-02-26 | Max Planck Gesellschaft | CONTRAST AGENTS FOR ULTRASONIC EXAMINATIONS AND METHOD FOR THE PRODUCTION THEREOF |
US4709703A (en) * | 1985-11-12 | 1987-12-01 | Mayo Foundation | Imaging system and method using radiopaque microspheres for evaluation of organ tissue perfusion |
US4794931A (en) * | 1986-02-28 | 1989-01-03 | Cardiovascular Imaging Systems, Inc. | Catheter apparatus, system and method for intravascular two-dimensional ultrasonography |
US5000185A (en) * | 1986-02-28 | 1991-03-19 | Cardiovascular Imaging Systems, Inc. | Method for intravascular two-dimensional ultrasonography and recanalization |
US5582178A (en) * | 1986-02-28 | 1996-12-10 | Cardiovascular Imaging Systems, Inc. | Method and apparatus for intravascular ultrasonography |
DE3643548C2 (en) * | 1986-12-19 | 1995-04-13 | Schering Ag | Ultrasound receiver for contrast medium detection |
US5040537A (en) * | 1987-11-24 | 1991-08-20 | Hitachi, Ltd. | Method and apparatus for the measurement and medical treatment using an ultrasonic wave |
US4799296A (en) * | 1987-12-29 | 1989-01-24 | Rasmussen Donald D | Connector for releasable securement to the free end of a lifting strap |
US4844882A (en) * | 1987-12-29 | 1989-07-04 | Molecular Biosystems, Inc. | Concentrated stabilized microbubble-type ultrasonic imaging agent |
DE3829999A1 (en) * | 1988-09-01 | 1990-03-15 | Schering Ag | ULTRASONIC METHOD AND CIRCUITS THEREOF |
US4957656A (en) * | 1988-09-14 | 1990-09-18 | Molecular Biosystems, Inc. | Continuous sonication method for preparing protein encapsulated microbubbles |
US5081997A (en) * | 1989-03-09 | 1992-01-21 | Vance Products Incorporated | Echogenic devices, material and method |
US5201314A (en) * | 1989-03-09 | 1993-04-13 | Vance Products Incorporated | Echogenic devices, material and method |
US5289831A (en) * | 1989-03-09 | 1994-03-01 | Vance Products Incorporated | Surface-treated stent, catheter, cannula, and the like |
US5042015A (en) * | 1989-09-01 | 1991-08-20 | Quantronix, Inc. | Measuring method and apparatus |
US5422861A (en) * | 1989-09-01 | 1995-06-06 | Quantronix, Inc. | Measuring method and apparatus |
US5220536A (en) * | 1989-09-01 | 1993-06-15 | Quantronix, Inc. | Measuring method and apparatus |
US5606534A (en) | 1989-09-01 | 1997-02-25 | Quantronix, Inc. | Laser-based dimensioning system |
US5105392A (en) * | 1989-09-01 | 1992-04-14 | Quantronix, Inc. | Measuring method and apparatus |
US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US6146657A (en) * | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US5776429A (en) * | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US6088613A (en) * | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US6001335A (en) * | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
US5230882A (en) * | 1989-12-22 | 1993-07-27 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5656211A (en) * | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
US5123414A (en) * | 1989-12-22 | 1992-06-23 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5334381A (en) * | 1989-12-22 | 1994-08-02 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5088499A (en) * | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5305757A (en) * | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5773024A (en) * | 1989-12-22 | 1998-06-30 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5469854A (en) * | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US20020150539A1 (en) * | 1989-12-22 | 2002-10-17 | Unger Evan C. | Ultrasound imaging and treatment |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US6989141B2 (en) * | 1990-05-18 | 2006-01-24 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US7083778B2 (en) * | 1991-05-03 | 2006-08-01 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US6613306B1 (en) | 1990-04-02 | 2003-09-02 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
IN172208B (en) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
US5578292A (en) | 1991-11-20 | 1996-11-26 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
USRE39146E1 (en) | 1990-04-02 | 2006-06-27 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
US5445813A (en) * | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
US20010024638A1 (en) * | 1992-11-02 | 2001-09-27 | Michel Schneider | Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof |
US20040208826A1 (en) * | 1990-04-02 | 2004-10-21 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
AU636481B2 (en) * | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
US20030194376A1 (en) * | 1990-05-18 | 2003-10-16 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US5215680A (en) * | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
US5236693A (en) * | 1990-11-14 | 1993-08-17 | Brigham And Women's Hospital | Medical ultrasound contrast agent and method of using same |
US5569180A (en) * | 1991-02-14 | 1996-10-29 | Wayne State University | Method for delivering a gas-supersaturated fluid to a gas-depleted site and use thereof |
GB9106686D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
US5874062A (en) * | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
US5147631A (en) * | 1991-04-30 | 1992-09-15 | Du Pont Merck Pharmaceutical Company | Porous inorganic ultrasound contrast agents |
AU2317592A (en) * | 1991-07-05 | 1993-02-11 | University Of Rochester | Ultrasmall non-aggregated porous particles entrapping gas-bubbles |
AU675050B2 (en) * | 1991-07-05 | 1997-01-23 | Nycomed Imaging As | Improvements in or relating to contrast agents |
US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
DE69230885T3 (en) * | 1991-09-17 | 2008-01-24 | Ge Healthcare As | GASOUS ULTRASONIC CONTRASTING AGENTS |
MX9205298A (en) | 1991-09-17 | 1993-05-01 | Steven Carl Quay | GASEOUS ULTRASOUND CONTRASTING MEDIA AND METHOD FOR SELECTING GASES TO BE USED AS ULTRASOUND CONTRASTING MEDIA |
US6723303B1 (en) | 1991-09-17 | 2004-04-20 | Amersham Health, As | Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane |
US5344640A (en) * | 1991-10-22 | 1994-09-06 | Mallinckrodt Medical, Inc. | Preparation of apatite particles for medical diagnostic imaging |
US5233995A (en) * | 1991-11-21 | 1993-08-10 | Sterling Winthrop Inc. | Encapsulated particles useful as contrast agents in ultrasound and x-ray imaging compositions and methods |
US5196183A (en) * | 1991-12-04 | 1993-03-23 | Sterling Winthrop Inc. | Contrast agents for ultrasound imaging |
US5255683A (en) * | 1991-12-30 | 1993-10-26 | Sound Science Limited Partnership | Methods of and systems for examining tissue perfusion using ultrasonic contrast agents |
GB9200388D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
IL104084A (en) | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them |
US5339814A (en) * | 1992-04-14 | 1994-08-23 | Lasker Sigmund E | Process for visualizing tissue metabolism using oxygen-17 |
US5327891A (en) * | 1992-07-30 | 1994-07-12 | Rammler David H | Catheter track and catheter for diagnosis and treatment |
US6383470B1 (en) | 1992-09-26 | 2002-05-07 | Thomas Fritzsch | Microparticle preparations made of biodegradable copolymers |
GB9221329D0 (en) | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
EP0680341B1 (en) * | 1993-01-25 | 2001-05-09 | Sonus Pharmaceuticals, Inc. | Phase shift colloids as ultrasound contrast agents |
IL108416A (en) | 1993-01-25 | 1998-10-30 | Sonus Pharma Inc | Phase shift colloids as ultrasound contrast agents |
US5650156A (en) * | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
US5997904A (en) * | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
JP3746293B2 (en) * | 1993-02-22 | 2006-02-15 | アメリカン バイオサイエンス、インコーポレイテッド | Methods for in vivo delivery of biologics and compositions therefor |
US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US20070122465A1 (en) * | 1993-02-22 | 2007-05-31 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US20030068362A1 (en) * | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US5701899A (en) * | 1993-05-12 | 1997-12-30 | The Board Of Regents Of The University Of Nebraska | Perfluorobutane ultrasound contrast agent and methods for its manufacture and use |
US5695740A (en) * | 1993-05-12 | 1997-12-09 | The Board Of Regents Of The University Of Nebraska | Perfluorocarbon ultrasound contrast agent comprising microbubbles containing a filmogenic protein and a saccharide |
US5716597A (en) * | 1993-06-04 | 1998-02-10 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
AU683485B2 (en) * | 1993-07-02 | 1997-11-13 | Molecular Biosystems, Inc. | Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas |
US5855865A (en) * | 1993-07-02 | 1999-01-05 | Molecular Biosystems, Inc. | Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas |
ES2231775T5 (en) | 1993-07-30 | 2011-02-02 | Imcor Pharmaceutical Co. | COMPOSITION OF STABILIZED MICROBUBBLES FOR ECOGRAPHY. |
US5798091A (en) | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
US7083572B2 (en) * | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
CN1068229C (en) | 1993-12-15 | 2001-07-11 | 勃勒柯研究有限公司 | Gas mixtures useful as ultrasound contrast media |
FR2716266A1 (en) * | 1994-02-16 | 1995-08-18 | Bargoin Roger | Detection of a body in tissue or blood vessel |
US5736121A (en) * | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
FR2721463A1 (en) | 1994-06-17 | 1995-12-22 | Trt Telecom Radio Electr | Digital radio transmission on at least two channels |
WO1998053855A1 (en) | 1997-05-30 | 1998-12-03 | Alliance Pharmaceutical Corp. | Methods and apparatus for monitoring and quantifying the movement of fluid |
GB9423419D0 (en) * | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
USRE38971E1 (en) * | 1995-01-31 | 2006-02-07 | Kabushiki Kaisha Toshiba | Ultrasound diagnostic apparatus and method |
US5830430A (en) * | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US5743266A (en) * | 1995-04-25 | 1998-04-28 | Molecular Biosystems, Inc. | Method for processing real-time contrast enhanced ultrasonic images |
US5560364A (en) * | 1995-05-12 | 1996-10-01 | The Board Of Regents Of The University Of Nebraska | Suspended ultra-sound induced microbubble cavitation imaging |
US5997898A (en) * | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US5674469A (en) * | 1995-06-07 | 1997-10-07 | Molecular Biosystems, Inc. | Gas-exchange method of making gas-filled microspheres |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US5820850A (en) * | 1995-06-07 | 1998-10-13 | Molecular Biosystems, Inc. | Gas-filled amino acid block co-polymer microspheres useful as ultrasound contrast agents |
US5897851A (en) * | 1995-06-07 | 1999-04-27 | Sonus Pharmaceuticals, Inc. | Nucleation and activation of a liquid-in-liquid emulsion for use in ultrasound imaging |
US6139819A (en) * | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US6033645A (en) * | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US6535210B1 (en) | 1995-06-07 | 2003-03-18 | Geovector Corp. | Vision system computer modeling apparatus including interaction with real scenes with respect to perspective and spatial relationship as measured in real-time |
US5706819A (en) * | 1995-10-10 | 1998-01-13 | Advanced Technology Laboratories, Inc. | Ultrasonic diagnostic imaging with harmonic contrast agents |
US5833613A (en) * | 1996-09-27 | 1998-11-10 | Advanced Technology Laboratories, Inc. | Ultrasonic diagnostic imaging with contrast agents |
US5648098A (en) * | 1995-10-17 | 1997-07-15 | The Board Of Regents Of The University Of Nebraska | Thrombolytic agents and methods of treatment for thrombosis |
US5611344A (en) * | 1996-03-05 | 1997-03-18 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
DK0904113T3 (en) * | 1996-03-05 | 2004-08-30 | Acusphere Inc | Microencapsulated fluorinated gases for use as imaging agents |
US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
WO1997040679A1 (en) | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US20020052310A1 (en) * | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
US6652837B1 (en) | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5976501A (en) * | 1996-06-07 | 1999-11-02 | Molecular Biosystems, Inc. | Use of pressure resistant protein microspheres encapsulating gases as ultrasonic imaging agents for vascular perfusion |
JPH105216A (en) * | 1996-06-19 | 1998-01-13 | Ge Yokogawa Medical Syst Ltd | Ultrasonic photographing method and apparatus and contast medium therefor |
US5849727A (en) * | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
US5837221A (en) * | 1996-07-29 | 1998-11-17 | Acusphere, Inc. | Polymer-lipid microencapsulated gases for use as imaging agents |
US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
US6017310A (en) * | 1996-09-07 | 2000-01-25 | Andaris Limited | Use of hollow microcapsules |
EP0977597B1 (en) * | 1996-09-11 | 2003-01-15 | Imarx Pharmaceutical Corp. | Improved methods for diagnostic imaging using a contrast agent and a vasodilator |
US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
US6106473A (en) * | 1996-11-06 | 2000-08-22 | Sts Biopolymers, Inc. | Echogenic coatings |
US7229413B2 (en) * | 1996-11-06 | 2007-06-12 | Angiotech Biocoatings Corp. | Echogenic coatings with overcoat |
US6068600A (en) * | 1996-12-06 | 2000-05-30 | Quadrant Healthcare (Uk) Limited | Use of hollow microcapsules |
US6143276A (en) * | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US6537246B1 (en) * | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6090800A (en) * | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US20050019266A1 (en) * | 1997-05-06 | 2005-01-27 | Unger Evan C. | Novel targeted compositions for diagnostic and therapeutic use |
US7452551B1 (en) | 2000-10-30 | 2008-11-18 | Imarx Therapeutics, Inc. | Targeted compositions for diagnostic and therapeutic use |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
CN100462066C (en) * | 1997-06-27 | 2009-02-18 | 美国生物科学有限公司 | Novel formulations of pharmacological agents, method for preparation thereof and method for use thereof |
US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
US6123923A (en) * | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
US6956021B1 (en) | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
US6444192B1 (en) | 1999-02-05 | 2002-09-03 | The Regents Of The University Of California | Diagnostic imaging of lymph structures |
US6689142B1 (en) * | 1999-04-26 | 2004-02-10 | Scimed Life Systems, Inc. | Apparatus and methods for guiding a needle |
US6254852B1 (en) | 1999-07-16 | 2001-07-03 | Dupont Pharmaceuticals Company | Porous inorganic targeted ultrasound contrast agents |
US6685645B1 (en) * | 2001-10-20 | 2004-02-03 | Zonare Medical Systems, Inc. | Broad-beam imaging |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
WO2001013891A2 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US20010036481A1 (en) * | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
GB9920392D0 (en) * | 1999-08-27 | 1999-11-03 | Nycomed Imaging As | Improvemets in or relating to diagnostic imaging |
US6302846B1 (en) * | 1999-09-20 | 2001-10-16 | Acuson Corporation | Ultrasound method for assessing ejection fraction using ultrasound contrast agents |
US6439236B1 (en) | 1999-10-25 | 2002-08-27 | The Board Of Regents Of The University Of Nebraska | Methods for inducing atrial and ventricular rhythms using ultrasound and microbubbles |
US6522292B1 (en) | 2000-02-23 | 2003-02-18 | Geovector Corp. | Information systems having position measuring capacity |
US7008535B1 (en) * | 2000-08-04 | 2006-03-07 | Wayne State University | Apparatus for oxygenating wastewater |
US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
CA2433335C (en) * | 2000-12-29 | 2010-04-20 | Advanced Inhalation Research, Inc. | Particles for inhalation having sustained release properties |
US7031875B2 (en) * | 2001-01-24 | 2006-04-18 | Geo Vector Corporation | Pointing systems for addressing objects |
US6866631B2 (en) * | 2001-05-31 | 2005-03-15 | Zonare Medical Systems, Inc. | System for phase inversion ultrasonic imaging |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
DK1455755T3 (en) * | 2001-11-20 | 2013-07-15 | Civitas Therapeutics Inc | Improved particle composition for delivery in lung |
US20030129250A1 (en) * | 2001-11-20 | 2003-07-10 | Advanced Inhalation Research Inc. | Particulate compositions for improving solubility of poorly soluble agents |
US7169155B2 (en) * | 2001-12-14 | 2007-01-30 | Scimed Life Systems, Inc. | Methods and apparatus for guiding a needle |
JP4842514B2 (en) * | 2002-03-20 | 2011-12-21 | エラン ファーマ インターナショナル,リミティド | Nanoparticle composition of angiogenesis inhibitor |
US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
US20040126400A1 (en) * | 2002-05-03 | 2004-07-01 | Iversen Patrick L. | Delivery of therapeutic compounds via microparticles or microbubbles |
JP3748848B2 (en) * | 2002-11-11 | 2006-02-22 | ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー | Ultrasonic diagnostic equipment |
US20040219961A1 (en) * | 2003-04-08 | 2004-11-04 | Ellenby Thomas William | Computer games having variable execution dependence with respect to spatial properties of a mobile unit. |
US7358226B2 (en) * | 2003-08-27 | 2008-04-15 | The Regents Of The University Of California | Ultrasonic concentration of drug delivery capsules |
US7908690B2 (en) * | 2003-09-30 | 2011-03-22 | Sentinelle Medical, Inc. | Supine patient support for medical imaging |
US7970452B2 (en) * | 2003-09-30 | 2011-06-28 | Hologic, Inc. | Open architecture imaging apparatus and coil system for magnetic resonance imaging |
US7379769B2 (en) * | 2003-09-30 | 2008-05-27 | Sunnybrook Health Sciences Center | Hybrid imaging method to monitor medical device delivery and patient support for use in the method |
US20080077005A1 (en) * | 2004-08-12 | 2008-03-27 | Piron Cameron A | System and Method for Multimodality Breast Imaging |
US20070003482A1 (en) * | 2004-01-15 | 2007-01-04 | Koninklijke Philips Electronic, N.V. | Ultrasound contrast agents for molecular imaging |
US7025726B2 (en) * | 2004-01-22 | 2006-04-11 | The Regents Of The University Of Nebraska | Detection of endothelial dysfunction by ultrasonic imaging |
US8076117B2 (en) * | 2004-03-18 | 2011-12-13 | Mayo Foundation For Medical Education And Research | Microbial biofilm removal methods and systems |
US8012457B2 (en) * | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
US7854705B2 (en) * | 2004-12-16 | 2010-12-21 | Olga Pawluczyk | Ex vivo verification of biopsy tissue samples |
US20060190812A1 (en) * | 2005-02-22 | 2006-08-24 | Geovector Corporation | Imaging systems including hyperlink associations |
WO2007025244A2 (en) | 2005-08-25 | 2007-03-01 | Houle Philip R | Treatment systems for delivery of sensitizer solutions |
JP2009039225A (en) * | 2007-08-07 | 2009-02-26 | Aloka Co Ltd | Imaging capsule |
US8290569B2 (en) * | 2007-11-23 | 2012-10-16 | Hologic, Inc. | Open architecture tabletop patient support and coil system |
US8797037B2 (en) | 2008-04-11 | 2014-08-05 | Baker Hughes Incorporated | Apparatus and methods for providing information about one or more subterranean feature |
US8253417B2 (en) | 2008-04-11 | 2012-08-28 | Baker Hughes Incorporated | Electrolocation apparatus and methods for mapping from a subterranean well |
US8841914B2 (en) | 2008-04-11 | 2014-09-23 | Baker Hughes Incorporated | Electrolocation apparatus and methods for providing information about one or more subterranean feature |
US8747331B2 (en) * | 2009-06-23 | 2014-06-10 | Hologic, Inc. | Variable angle guide holder for a biopsy guide plug |
WO2011035140A1 (en) | 2009-09-18 | 2011-03-24 | Paka Pulmonary Pharmaceuticals, Inc. | Methods and compositions for delivery of contrast moieties to the lungs |
EP2537051B1 (en) | 2010-02-20 | 2013-12-18 | Baker Hughes Incorporated | Apparatus and methods for providing information about one or more subterranean variables |
US9332926B2 (en) | 2010-11-25 | 2016-05-10 | Invivo Corporation | MRI imaging probe |
US10279053B2 (en) | 2011-07-19 | 2019-05-07 | Nuvox Pharma Llc | Microbubble compositions, method of making same, and method using same |
US10219887B2 (en) | 2013-03-14 | 2019-03-05 | Volcano Corporation | Filters with echogenic characteristics |
US10292677B2 (en) | 2013-03-14 | 2019-05-21 | Volcano Corporation | Endoluminal filter having enhanced echogenic properties |
US20160030151A1 (en) | 2013-03-14 | 2016-02-04 | Volcano Corporation | Filters with echogenic characteristics |
CA2905730C (en) | 2013-03-15 | 2022-06-21 | Hologic, Inc. | System and method for reviewing and analyzing cytological specimens |
JP2016517333A (en) | 2013-03-15 | 2016-06-16 | ボルケーノ コーポレイション | Distal protection system and method with pressure and ultrasound capabilities |
US9097097B2 (en) | 2013-03-20 | 2015-08-04 | Baker Hughes Incorporated | Method of determination of fracture extent |
JP2017528263A (en) | 2014-09-24 | 2017-09-28 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | Intraluminal filter with improved echogenic properties |
EP3419742B1 (en) * | 2016-02-25 | 2022-12-14 | King Abdullah University Of Science And Technology | Acoustically excited encapsulated microbubbles and mitigation of biofouling |
US20210361304A1 (en) * | 2020-05-18 | 2021-11-25 | Agitated Solutions Inc. | Reducing Pulmonary Hypertension with Nitric Oxide Microbubbles |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3640271A (en) * | 1969-06-30 | 1972-02-08 | Ibm | Blood flow pressure measurement technique employing injected bubbled and ultrasonic frequency scanning |
US3739636A (en) * | 1971-01-22 | 1973-06-19 | A Versaci | Linear readout flowmeter |
US4143554A (en) * | 1977-03-14 | 1979-03-13 | Second Foundation | Ultrasonic scanner |
US4122713A (en) * | 1977-05-19 | 1978-10-31 | Medtronic, Inc. | Liquid velocity measuring system |
US4247406A (en) * | 1979-04-23 | 1981-01-27 | Widder Kenneth J | Intravascularly-administrable, magnetically-localizable biodegradable carrier |
US4276885A (en) * | 1979-05-04 | 1981-07-07 | Rasor Associates, Inc | Ultrasonic image enhancement |
US4265251A (en) * | 1979-06-28 | 1981-05-05 | Rasor Associates, Inc. | Method of determining pressure within liquid containing vessel |
US4316391A (en) * | 1979-11-13 | 1982-02-23 | Ultra Med, Inc. | Flow rate measurement |
US4315435A (en) * | 1980-06-30 | 1982-02-16 | Second Foundation | Dual scan ultrasonic scanner |
DE3173476D1 (en) * | 1980-11-17 | 1986-02-20 | Schering Ag | Composition generating microbubbles |
DE3141641A1 (en) * | 1981-10-16 | 1983-04-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | ULTRASONIC CONTRAST AGENTS AND THEIR PRODUCTION |
-
1983
- 1983-01-27 US US06/461,664 patent/US4572203A/en not_active Expired - Lifetime
-
1984
- 1984-01-26 DE DE19843490013 patent/DE3490013T1/en active Granted
- 1984-01-26 WO PCT/US1984/000135 patent/WO1984002838A1/en active IP Right Grant
- 1984-01-26 GB GB08423446A patent/GB2143327B/en not_active Expired
- 1984-01-26 EP EP84901032A patent/EP0135563B1/en not_active Expired - Lifetime
- 1984-01-26 FR FR848401207A patent/FR2541108B1/en not_active Expired - Lifetime
- 1984-01-26 IL IL70784A patent/IL70784A/en not_active IP Right Cessation
- 1984-01-26 NL NL8420041A patent/NL191079C/en not_active IP Right Cessation
- 1984-01-26 AU AU25769/84A patent/AU571863B2/en not_active Ceased
- 1984-01-26 AT AT0900484A patent/AT397034B/en not_active IP Right Cessation
- 1984-01-26 JP JP59501032A patent/JPS60500486A/en active Granted
- 1984-01-27 CA CA000446243A patent/CA1221759A/en not_active Expired
- 1984-09-25 SE SE8404797A patent/SE466634B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE3490013T1 (en) | 1985-02-21 |
SE466634B (en) | 1992-03-16 |
WO1984002838A1 (en) | 1984-08-02 |
AT397034B (en) | 1994-01-25 |
SE8404797D0 (en) | 1984-09-25 |
JPH0224139B2 (en) | 1990-05-28 |
NL191079B (en) | 1994-08-16 |
FR2541108A1 (en) | 1984-08-24 |
FR2541108B1 (en) | 1992-04-03 |
EP0135563A4 (en) | 1987-10-05 |
ATA900484A (en) | 1993-06-15 |
GB2143327A (en) | 1985-02-06 |
NL8420041A (en) | 1984-12-03 |
IL70784A (en) | 1987-12-31 |
DE3490013C2 (en) | 1990-03-15 |
GB8423446D0 (en) | 1984-10-24 |
IL70784A0 (en) | 1984-04-30 |
US4572203A (en) | 1986-02-25 |
AU2576984A (en) | 1984-08-15 |
GB2143327B (en) | 1986-10-22 |
JPS60500486A (en) | 1985-04-11 |
SE8404797L (en) | 1984-09-25 |
AU571863B2 (en) | 1988-04-28 |
NL191079C (en) | 1995-01-16 |
EP0135563B1 (en) | 1990-08-29 |
EP0135563A1 (en) | 1985-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1221759A (en) | Ultrasonic imaging technique | |
US4718433A (en) | Contrast agents for ultrasonic imaging | |
Tiemann et al. | Real‐time contrast echo assessment of myocardial perfusion at low emission power: first experimental and clinical results using power pulse inversion imaging | |
CA1171952A (en) | Ultrasonic image enhancement | |
US6080386A (en) | Suspended ultra-sound induced microbubble cavitation imaging | |
Harvey et al. | Advances in ultrasound | |
US4681119A (en) | Method of production and use of microbubble precursors | |
US4657756A (en) | Microbubble precursors and apparatus for their production and use | |
WO1994009703A1 (en) | Surfactant-stabilized microbubble mixtures, process for preparing and methods of using the same | |
de Jong | Improvements in ultrasound contrast agents | |
EP1909908A1 (en) | Ultrasound treatment system | |
Martina et al. | Ultrasound contrast agents for brain perfusion imaging and ischemic stroke therapy | |
Cosgrove | Echo-enhancing (ultrasound contrast) agents | |
US5236693A (en) | Medical ultrasound contrast agent and method of using same | |
Schlief et al. | Saccharide based contrast agents | |
Burns et al. | Contrast agents for echocardiography: principles and instrumentation | |
Nanda | Echocontrast enhancers—how safe are they? | |
Ragavendra et al. | Harmonic imaging of porcine intraovarian arteries using sonographic contrast medium: initial findings | |
Villarraga et al. | Harmonic imaging during contrast echocardiography: basic principles and potential clinical value | |
BALZER | REINHARD SCHLIEF, ROLF SCHÜRMANN, THOMAS BALZER, MICHAEL ZOMACK & HANS-PETER NIENDORF | |
Ortman | Contrast Agents and Contrast Imaging in Ultrasound | |
Schrope et al. | Polymeric systems for diagnostic ultrasound contrast agents | |
Fowlkes et al. | Microbubbles for ultrasound diagnosis and therapy | |
Harvey et al. | Ultrasound: Future Directions | |
CHUNG | 28. Harmonic imaging during contrast echocardiography: basic principles and potential clinical value HECTOR R. VILLARRAGA, DAVID A. FOLEY, SANG MAN CHUNG, NAVIN C. NANDA & SHARON L. MULVAGH |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |